Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

REHOVOT, Israel and HOBOKEN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the U.S. Food and Drug Administration (FDA) has approved Kamada Plasma's collection center in San Antonio, TX. The approval was obtained following an on-site inspection made by the FDA during February 2026.